VolitionRx — Building real-world Nu.Q NETs sepsis data
Volition continues to build data demonstrating that the Nu.Q® NETs H3.1 diagnostic platform is a potential breakthrough tool in sepsis management....
184 Views
VolitionRx - Termination of coverage
Edison Investment Research is terminating coverage on VolitionRx (VNRX), Murray Income Trust (MUT) and NioCorp Developments (NB). Please note you...
502 Views
VNRX: Reports 3Q 2024 results. Over 110
Volition's Nu.Q Vet Canine Cancer Screening Test now available in 17 countries, particularly by Antech on its Element I+ diagnostic...
237 Views
VNRX: Cost cutting being implemented in a plan to be cash flow neutral in 2025. Revenues from Nu.Q Vet Test Expected to Accelerate During 2H 2024
Volition's Nu.Q Vet Canine Cancer Screening Test are being launched in the U.S. and Europe by Antech on its Element I+ diagnostic point-of-sale...
207 Views
VolitionRx - Snaring sepsis, with early NETs detection
VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These...
280 Views